Objective: Squamous cell carcinoma (SCC) of the rectum is rare, but as with anal cancer, risk may be increased among immunosuppressed individuals. We assessed risk of rectal SCC in HIV-infected people.
Introduction
Colorectal cancer is a major cause of morbidity and mortality, with 132 700 incident cases and 49 700 deaths estimated for the US in 2015 [1] . The vast majority of colorectal cancer cases are adenocarcinomas [2] . In contrast, squamous cell carcinoma (SCC) in the colorectum is extremely rare. In the US, SCCs constitute only 1-2% of diagnosed rectal tumours with an annual incidence of 1.54 per 1 000 000 person-years in males and 3.00 per 1 000 000 person-years for females [3] .
Because of the rarity of rectal SCC, little is known about its aetiology. To date, there are fewer than 100 published case reports since the first case described in 1919 [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Human papillomavirus (HPV) has been proposed as an etiologic agent for rectal SCC because of the proximity of the rectum to the anus and the known role of HPV in anal SCC, but results of HPV testing in rectal SCC tumours have been conflicting [7, [9] [10] [11] [12] . Reports published since 2000 often note the co-occurrence of ulcerative colitis [4, 8, 10, 11] , pointing to inflammation as another possible co-factor. Although the rectum does not normally contain squamous epithelium, tumours might theoretically originate from areas of squamous metaplasia arising in the presence of inflammatory damage. The occurrence of such rectal squamous metaplasia has been documented in patients with ulcerative colitis, including a report of rectal squamous metaplasia occurring 7 years prior to the diagnosis of rectal SCC [11, 14] .
Two of the most recent case reports have described rectal SCC occurring in HIV-infected males [9, 12] . In preliminary data generated for a study describing cancer trends in HIV-infected people [15] , we noted that approximately 30% of rectal cancers in HIV-infected persons were SCCs (unpublished observations). This high proportion, relative to the 1-2% observed in the general population, suggests that progressive immunodeficiency caused by HIV infection (i.e. AIDS) may be an unidentified risk factor for rectal SCC. Although HIVinfected people do not have an increased risk of colorectal cancer overall [16, 17] , prior studies have not specifically examined the association with rectal SCC. Notably, HIVinfected persons have a strongly increased risk of anal cancer [16] [17] [18] , and there may be etiologic similarity between rectal SCC and anal cancer (which is primarily also a SCC). However, because of the overall rarity of rectal SCC and the contiguous location of the rectum and the anal canal, there may also be site misclassification of anal SCC as rectal SCC.
In light of these possibilities, the objective of our study was to quantify the risk of rectal SCC in HIV-infected persons, both overall and within the group most likely to have anal HPV infection (i.e. MSM). We used data from the HIV/AIDS Cancer Match (HACM) Study (http:// hivmatch.cancer.gov/) [19] , a linkage of HIV and cancer registries, which provided information on cancer for a large population-based sample of HIV-infected people. We explored the possibility that rectal SCC may represent misclassified anal cancer through the examination of case notes collected by cancer registries. In addition, we estimated the risk of rectal SCC in solid organ transplant recipients, another immunosuppressed population, using data from the Transplant Cancer Match Study.
Methods
The present study used data from the following HIV registries in the HACM Study that provided information on people registered with HIV infection with and without a prior AIDS diagnosis: Colorado, Connecticut, Florida, Georgia, Michigan, New Jersey, and Texas. We included cancers diagnosed during years when HIV infection and AIDS diagnoses were both reported to HIV registries and years when cancer registries had completed ascertainment of cases at the time of the data linkage. We assessed rectal cancer [International Classification of Diseases for Oncology version 3 (ICD-O3) topography code C209] and, for comparison, colon cancer (ICD-O3 codes C180-189 or C260) and anal cancer (ICD-O3 codes C210-212 or C218). We further classified cases based upon their histological diagnosis, either as SCC or non-SCC. The following ICD-O3 histology codes provided by the cancer registries were used to define SCC status: 8052, 8070, 8071, 8072, 8073, 8074, 8075, 8076, 8077, 8078, 8083, and 8084. The remaining histologies were classified as non-SCC, excluding Kaposi sarcoma, lymphoma, mesothelioma, and poorly specified subtypes. The specific histologies classified as non-SCC among the identified HIV-infected cases and in the general population are included in Supplemental Table 1 , http://links.lww.com/QAD/A773. We define outcomes as anal SCC, rectal SCC, rectal non-SCC, and colon non-SCC and consider only the first diagnosis for each cancer outcome.
We calculated standardized incidence ratios (SIRs) to compare cancer risk in HIV-infected people to risk in the general population, comprised almost entirely of HIVuninfected individuals. SIRs are defined as the number of observed cases divided by the number expected based on general population rates (standardized to the HIV population by age, sex, race/ethnicity, calendar year, and cancer registry). We estimated SIRs overall and separately based on sex and HIV risk category [MSM, non-MSM male IDU, male heterosexual, female IDU, female heterosexual, other/unknown]. We further used Poisson regression to estimate rectal SCC rates and assess potential risk factors for rectal SCC among HIV-infected people, including sex and HIV risk category, attained age, race/ethnicity, and degree of immunosuppression [prior AIDS diagnosis vs. no AIDS (i.e. HIV-only)]. Follow-up for cancer diagnoses among the HIV-infected individuals accrued from the latest of HIV report or, AIDS diagnosis, and beginning of cancer registration. Follow-up ended at the earliest of death or end of cancer registration.
To examine potential misclassification of the cancer outcomes, we requested de-identified case notes from four of the participating registries (Colorado, Michigan, New Jersey, and Texas) on a proportion of anal and rectal cancer cases (SCC and non-SCC) from HIV-infected people (i.e. cancer registry cases that matched to a record in the HIV registry), as well as a comparison set of HIVuninfected cases (i.e. cancer registry cases that did not match to the HIV registry). One cancer registrar, one HIV clinician, and two cancer epidemiologists (AC, EE, MS, and RR) independently reviewed the case notes for each individual and assigned a location (anus, rectum) and histology to the tumour. Reviewers utilized the available information on biopsy and tumour location as well as treatment administration to determine the most likely location. Detailed disease reports and supporting medical records beyond the summary provided by the cancer registries were not available. Reviewers were blinded to the HIV status and risk category.
For any case that the reviewer classified as rectal SCC, a level of confidence was noted on a scale from 1-5 (1 ¼ very uncertain, 2 ¼ somewhat uncertain, 3 ¼ more likely than not, 4 ¼ somewhat certain, 5 ¼ very certain). Scores 4 greater than or equal to 4 were considered to indicate high confidence based on the amount of supporting information (e.g., rectum consistently listed as location in both diagnosis and treatment notes), and scores less than 4 were assigned to cases with little supporting data (e.g. rectum SCC listed but no supporting diagnostic or treatment notes). Rectal SCC cases without conflicting information or information specifically pointing to an anal cancer diagnosis remained classified as rectal SCC cases. Any disagreements in the classification assigned between the four reviewers were resolved by consensus. According to patient HIV status, we report the proportion of all reviewed cases in our sample for which either site or histology was reassigned by consensus and the proportion of reviewed rectal SCC cases that were classified as such with 'high confidence' by at least one reviewer.
To determine whether misclassification could account for the excess of rectal SCC in HIV-infected persons, we recalculated the SIR using the results of the case review under two conditions. First, after estimating the proportion p 1 of reviewed rectal SCC cases that were potentially misclassified, we recalculated the SIR using only the remaining proportion of the observed rectal SCC cases (1-p 1 ). Secondly, we recalculated the SIR after removing the proportion of cases p 2 that were not scored as high confidence by at least one independent reviewer.
To further explore the potential association between immunosuppression and rectal SCC, we examined rectal SCC risk in solid organ transplant recipients. Transplant recipients are administered immunosuppressive medications to prevent graft rejection and represent a patient population with distinct risk factors from HIV-infected persons but who also experience immunosuppression. We evaluated the risk of rectal SCC in transplant recipients using data from the Transplant Cancer Match (TCM) Study. The TCM Study is designed similarly to the HACM Study, linking data from the US transplant registry to multiple cancer registries (http://transplantmatch.cancer.gov/) [20] . We calculated SIRs comparing the number of cancers occurring after transplant to the expected number based on general population rates.
Results
We identified 295 738 HIV-infected people in seven US states, of whom 1189 were diagnosed with anal cancer (64.4%), rectal cancer ( Among HIV-infected people, incidence of rectal SCC was higher in MSM compared with other HIVinfected groups [incidence rate ratio (IRR) ¼ 3.44; 95% CI 1.96-6.03] ( Table 2 ). Persons at least 30 years of age had a higher risk for rectal SCC than those less than 30 years of age, as did whites compared with nonwhites, although neither association was significant after multivariable adjustment. The incidence of rectal SCC did not appreciably change over time during the HAART era. Finally, people diagnosed with AIDS had higher rectal SCC incidence than those with HIV-only (IRR¼1.92; 95% CI 1.08-3.42).
To explore the possibility that some rectal SCCs were misclassified anal cancers, we reviewed the case abstracts for 113 cases from four cancer registries, including 73 rectal SCC cases (55 HIV-infected, 18 HIV-uninfected). Examples of the information available on these cases along with some brief comments are given in Table 3 . The level of detail varied, ranging from only a simple statement of the diagnosis to information on locations of biopsies and treatment received. For certain cases, information on the location of the tumour mass in different parts of the abstract was conflicting and often indicated that the tumour spanned the anorectal region; we classified these tumours as anal cancers because the site code for 'anorectal lesion' (C218) is classified as anal cancer (http://apps.who.int/classifications/icd10/). Approximately one-third of rectal SCC cases were 108 AIDS 2016, Vol 30 No 1 Table 2 as well as cancer registry. The level of detail for these more probable HIV-infected rectal SCCs varied in quality as well (Supplemental Table  2 , http://links.lww.com/QAD/A773). Among the 21 'high confidence' cases, certain treatment details were provided for 11, with combination radiotherapy and chemotherapy most often listed. Specific location of the tumour within the rectum (i.e. proximal or distal rectum) was mostly missing, with the exception of case 21b, which was described as a tumour at 6-12 cm from the anal verge. Advanced tumours may be more likely to span the anorectal region and be misclassified. Although detailed information on tumour size was not available, the stage distribution among this set of 21 cases did not appear to be heavily skewed towards advanced disease (11 local tumours, four regional tumours, one distant tumour, five unknown).
Discussion
This is the first report to demonstrate that HIV-infected people have a markedly elevated risk for rectal SCC. This excess risk was most pronounced in HIV-infected MSM, a risk pattern very similar to that observed for anal SCC, which is caused by HPV. Notably, risk estimates for rectal SCC differed from those for nonsquamous rectal tumours and colon cancer. We eliminated obvious misclassification of anal SCC as rectal SCC. Some misclassification may have remained, but the extent to which this was the explanation for the excess incidence associated with HIV infection could not be determined without detailed information on tumour location.
Very little is known about risk factors for developing rectal SCC due to its rarity. Meta-analyses of studies of cancer risk in HIV-infected people show no consistent evidence of increased colorectal cancer risk, but these studies combined both colon and rectal cancers and did not separate histologic subtypes [16, 21] . The absence of an elevated risk is not surprising because, as we observed in this study, most colorectal cancers in HIV-infected people are still non-SCCs. Interestingly, the failure to evaluate colon and rectal tumours as distinct in prior studies may have also precluded the ability to observe a deficit of colon cancer in HIV-infected persons, as documented here.
In support of a role for immunosuppression as a risk factor for rectal SCC, we found a higher risk in HIV-infected people who had progressed to AIDS than in HIV-infected people who had not. In addition, we report here that rectal SCC risk was elevated among transplant recipients, another immunosuppressed patient population. Prior studies of transplant recipients have demonstrated a modest increase in colorectal cancer overall [20, 21] but the evaluation of all colorectal cancers together likely missed the stronger association specific to rectal SCC.
Given the anatomic continuity of the anal canal and the rectum, it is relevant to consider the aetiology of anal cancer. Anal cancer is caused by infection with HPV-16 or, to a lesser extent, other oncogenic subtypes of HPV [22] . HIV-infected persons have an elevated risk of developing anal cancer [16] [17] [18] , and long-term immunosuppression is a risk factor for anal cancer among HIVinfected individuals [23, 24] . Our data further confirm previous observations that MSM have a particularly increased risk of anal neoplasia [23, 25] . This high risk is largely due to a high prevalence of receptive anal sex practices, which increases the chance of HPV acquisition [26, 27] .
In our study, the patterns for rectal SCC mirrored those for anal SCC, suggesting HPV infection could also be a contributing cause of rectal SCC. Specifically, HIVinfected MSM had the greatest elevation in rectal SCC. The elevation for rectal SCC was smaller in transplant recipients who, although immunosuppressed, may be less likely than HIV-infected MSM to have anal HPV infection. In addition, US population trends in anal and rectal SCC incidence have recently been reported to be similar [3] , providing further evidence that SCC aetiology may be similar across the anorectal region. Prior studies have documented HPV DNA positivity in some rectal SCC tumours, as well as the presence of either HPV oncoprotein transcripts or altered levels of HPV-targeted tumour suppressor proteins [11] [12] [13] . However, these reports are limited to less than 10 cases, and two other studies using different assays, including in-situ hybridization, reported negative results for the presence of HPV [8, 10] .
Our observation of a strong association between HIV and rectal cancer specific to SCC histology may have been due in part to misclassification of anal SCCs as rectal SCCs. The rectal and anal regions are continuous, and large tumours can span both regions, making them difficult to distinguish. Our greatest challenge was the limited data available in the cancer registries to assess the diagnoses. To some extent, the uncertainty is unavoidable, as there is inherent clinical ambiguity. It was reassuring that the rectal SCC cases that appeared to be misclassified anal cancers were equally present in both HIV-infected persons and the general population, pointing to nondifferential misclassification. When we removed the cases that were probable anal cancers from the HIV-infected rectal SCC group, a nearly 20-fold excess risk of rectal SCC remained. Furthermore, we calculate that nearly 90% of the 89 rectal SCC cases reported in HIV-infected persons would have to be misclassified, leaving fewer than eight cases, to result in no excess risk compared with the general population (i.e. SIR <1). On the other hand, because rectal SCCs are not common, any misclassification would not substantially affect the SIRs for anal cancer. For instance, even if all of these 89 observed rectal SCCs were in fact anal SCCs, the SIR for anal SCC would only increase from 38 to 42. Future work requires a greater level of detail on tumour size and location within the rectum, with demonstration of the presence of small, proximal SCCs of the rectum needed to conclusively prove that rectal SCC is a distinct entity from anal SCC.
Strengths of our registry-based study include a large enough HIV population to gather an adequate number of cancers classified by both tumour site and histology. This proved crucial for documenting previously unappreciated associations, which were masked by examination of colorectal cancer or rectal cancer overall. Our design also allowed us to compare across tumour sites, providing support for a similar aetiology between rectal and anal SCC. Also unique to this study was access to cancer registry case notes, which allowed us to assess the potential misclassification of cancer sites. Limitations must also be noted, including a lack of conclusive details for some tumours due to factors such as clinical ambiguity and poor documentation. We also lacked data on HIV treatment and CD4 þ T-cell counts, which prevented more detailed examination of the role of immunosuppression. We did not have access to tumour tissues, which would have allowed us to test directly the hypothesis that HPV is etiologically relevant for rectal SCC as a distinct entity in the context of HIV infection.
We have shown that HIV-infected individuals are at an elevated risk of developing rectal SCC. The increased risk of rectal SCC among HIV-infected people occurred in a pattern very similar to anal cancer (i.e. particularly high in MSM), suggesting a sexually transmitted infectious aetiology such as HPV. We also documented higher risk in people with AIDS than in other HIV-infected people, as well as elevated risk in transplant recipients, pointing to a role for immunosuppression. Although we observed ambiguity and misclassification between anal SCC and rectal SCC that could account for a proportion of the excess rectal SCC risk observed, the results are also consistent with squamous tumours with shared aetiology (i.e. likely HPV) arising not only in the anal canal but also the rectum and occurring most frequently among HIVinfected MSM. The views expressed in this article are those of the authors and should not be interpreted to reflect the views or policies of the National Cancer Institute, HIV/AIDS or cancer registries, or their contractors. This research was supported in part by the Intramural Research Program of the National Cancer Institute.
